On October 14, 2021, Netherton, Matthew; Brucelle, Francois published a patent.Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the patent was Preparation of substituted hydroxyphenylpyridazinamines for treating BAF complex-related disorders. And the patent contained the following:
The present disclosure features compounds I [X1 = O or NR2; each X2 = (independently) halo; k = 0-4; m = 0-4; R1 = halo or (un)substituted alkyl; R2 = H or (un)substituted alkyl; L1 = (un)substituted alkylene; L = L2(L3)n; n = 0-3; L2 = (un)substituted alkylene, heteroalkylene, or heterocyclylene; each L3 = (independently) O, (un)substituted heteroalkylene, carbocyclylene, etc.; and D = a degradation moiety] or pharmaceutically acceptable salts thereof, useful for the treatment of BAF complex-related disorders. E.g., a multi-step synthesis of II, starting from 4-bromo-6-chloropyridazin-3-amine and Et 2-(piperazin-1-yl)acetate, was described. Exemplified compounds I were evaluated for their ability to degrade a HiBit-BRM or HiBit-BRG1 fusion protein in a cell-based degradation assay (data given). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate
The Article related to hydroxyphenylpyridazinamine preparation baf complex related disorder, brm brg1 fusion protein degradation hydroxyphenylpyridazinamine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem